NCT05047991 - Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

October 31, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2024

Conditions

Pancreatic Cancer Non-resectablePancreatic Cancer Metastatic

Interventions

DRUG

Irinotecan Liposome Injection

Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle

DRUG

Fluorouracil

5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle

DRUG

Leucovorin

Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle

DRUG

Oxaliplatin

Oxaliplatin, intravenously, over 2 h on day 1 and day 15 of every 28-day cycle

DRUG

Nab paclitaxel

Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle

DRUG

Gemcitabine

Gemcitabine, intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle